department

Clinical
Regulatory
Medical Affairs
Commercial
R&D / Discovery
Biostatistics / Data
Manufacturing / CMC
Market Access

therapeutic area

Oncology
Immunology
Neuroscience
Cardiovascular
Metabolic
Rare Disease
Infectious Disease

location & type

Remote Only
US Only
California
Massachusetts
Internships
Phase 3 Roles
All Jobs →

when

Latest
Archive

by source

All Sources
Sources Page

by activity

Most Active
Biggest Pipelines
Recently Active

hiring

Companies Hiring Now
Big Pharma Roles
All Companies →

Drugs & Pipeline

intelligence

Drugs
Patent Cliff

research

Publications
Topics

window

Next 90 Days
All (incl. Past)

by type

PDUFAs
Approvals
Earnings
Readouts

Sign In Subscribe

pharmadog

fetch the data · sniff the signal

Discover

Calendar
Drugs
Companies
News

Hubs

Topics
Jobs
Patent cliff
Publications

Tools

Compare
Search
Bookmarks

Trust

About
Sources
Contact

Legal

Privacy
Terms
Pricing

© 2026 pharmadog.xyz

made by humans and a good dog

home
jobs
news
cal
search

Ezetimibe · pharmadog

pharmadog
drugs
Ezetimibe

drug

patient view →

ezetimibe

Marketedupdated 2mo ago

by OEP Pharma

Approved

community read0 votes

all catalysts(0)

nothing on the calendar yet

News(0)

no news has mentioned this drug yet

brand

Ezetimibe

generic

ezetimibe

indication

Heterozygous Familial Hypercholesterolemia (heFH)

phase

marketed

🐶 often sniffed alongside

top 8

companyGlenmark Pharmaceuticals Ltd6 co-mentions · 2 sources
tagRecall3 co-mentions · 3 sources
drugsimvastatin2 co-mentions · 1 sources
drugFlolipid2 co-mentions · 1 sources
companyRemedyRepack Inc2 co-mentions · 1 sources
drugBISOPROLOL FUMARATE AND HYDROCHLOROTHIAZIDE1 co-mentions · 1 sources
drugBISOPROLOL FUMARATE1 co-mentions · 1 sources
drugALDACTAZIDE1 co-mentions · 1 sources

Patent cliff

source: FDA Orange Book

first barrier falls

May 1, 2033

~6.8 years out

Earliest of all listed patents + FDA exclusivities. Generic / biosimilar entry typically only becomes possible AFTER both patent and exclusivity barriers expire.

patents (10)

May 1, 2033formulationUS 10376470
May 1, 2033formulationUS 10376470
May 1, 2033formulationUS 10376470
May 1, 2033formulationUS 10376470
May 1, 2033formulationUS 9763885
May 1, 2033formulationUS 9763885
May 1, 2033formulationUS 9763885
May 1, 2033formulationUS 9763885
Apr 30, 2026patentUS 7612058*PED
Oct 30, 2025method-of-use (U-1027)US 7612058

Data sources

ClinicalTrials.gov

last refreshed 55m ago

Found something off?

🐶 something off?

Report a data issue

Tell Bork what looks wrong — wrong sponsor, stale phase, mislinked ticker, anything. We’ll triage and fix.

comments(0)

5-min edit window · permanent after that

sign in to leave a comment · permanent archive after 5 minutes

no comments yet — first sniff?

Trials studying ezetimibe

—A Study of Bempedoic Acid in Combination With Ezetimibe and Either Rosuvastatin or Atorvastatin in Patients With Primary Hypercholesterolemia or Mixed Dyslipidemiarecruitingn=2,000
phase3A CCTA Imaging Trial to Evaluate the Effect of Obicetrapib/Ezetimibe on Coronary Plaqueactive not recruitingn=300
—A Study of Bempedoic Acid or Its Single-pill Combination Therapy With Ezetimibe in Patients With Primary Hypercholesterolaemia or Mixed Dyslipidaemiaactive not recruitingn=2,560
phase3A Study to Evaluate the Efficacy and Safety of Enlicitide (MK-0616, Oral PCSK9 Inhibitor) Compared With Ezetimibe or Bempedoic Acid or Ezetimibe and Bempedoic Acid in Adults With Hypercholesterolemia (MK-0616-018/CORALreef AddOn)completedn=301
—Treatment With Bempedoic Acid and/or Its Fixed-dose Combination With Ezetimibe in Primary Hypercholesterolemia or Mixed Dyslipidemiaactive not recruitingn=5,000
phase3A Study of Bempedoic Acid/Ezetimibe/High-intensity Statin in Patients Without Cardiovascular Eventsnot yet recruitingn=103
phase3A Study to Evaluate the Effect of Obicetrapib/Ezetimibe 10 mg Fixed-Dose Combination or Obicetrapib 10 mg Daily on Top of Guideline-Recommended Lipid-Lowering Therapy in Participants With Type 2 Diabetes and/or Metabolic Syndromerecruitingn=300
N/AModerate-intensity Statin vs. Individualized LDL-C Target-based Therapy in Older Adults With Type 2 Diabetes (iTARGET-Elderly Study)recruitingn=2,186

more trials →